- Home
- BAH vs NBIX Comparison
BAH vs NBIX Comparison
Compare BAH & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAH
- NBIX
- Stock Information
- Founded
- BAH 1914
- NBIX 1992
- Country
- BAH United States
- NBIX United States
- Employees
- BAH N/A
- NBIX N/A
- Industry
- BAH Professional Services
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BAH Consumer Discretionary
- NBIX Health Care
- Exchange
- BAH Nasdaq
- NBIX Nasdaq
- Market Cap
- BAH 12.0B
- NBIX 14.4B
- IPO Year
- BAH 2010
- NBIX 1996
- Fundamental
- Price
- BAH $85.69
- NBIX $154.77
- Analyst Decision
- BAH Hold
- NBIX Strong Buy
- Analyst Count
- BAH 11
- NBIX 18
- Target Price
- BAH $119.20
- NBIX $172.06
- AVG Volume (30 Days)
- BAH 2.7M
- NBIX 1.0M
- Earning Date
- BAH 10-24-2025
- NBIX 10-28-2025
- Dividend Yield
- BAH 2.57%
- NBIX N/A
- EPS Growth
- BAH 3.12
- NBIX 12.44
- EPS
- BAH 6.54
- NBIX 4.19
- Revenue
- BAH $11,706,000,000.00
- NBIX $2,682,700,000.00
- Revenue This Year
- BAH $2.06
- NBIX $23.68
- Revenue Next Year
- BAH $5.14
- NBIX $18.02
- P/E Ratio
- BAH $13.08
- NBIX $36.93
- Revenue Growth
- BAH 2.42
- NBIX 19.61
- 52 Week Low
- BAH $82.23
- NBIX $84.23
- 52 Week High
- BAH $190.59
- NBIX $157.67
- Technical
- Relative Strength Index (RSI)
- BAH 34.67
- NBIX 67.44
- Support Level
- BAH $84.84
- NBIX $133.62
- Resistance Level
- BAH $87.72
- NBIX $157.67
- Average True Range (ATR)
- BAH 3.26
- NBIX 4.47
- MACD
- BAH -0.47
- NBIX 1.07
- Stochastic Oscillator
- BAH 17.32
- NBIX 87.92
About BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.